Yahoo · Sep 16, 2026
STERIS Stock: Is STE Underperforming the Healthcare Sector?
STERIS has trailed the broader market over the past year, while Wall Street analysts remain cautiously optimistic about the company’s future prospects.
NYSE · STE
STERIS plc
Healthcare · Medical - Devices
$205.04
Down-$3.00 (-1.44%)
Updated Sep 20, 2026, 11:24 AM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 24.83B
- P/E ratio
- 36.07
- Dividend yield
- 1.17%
- 52-week range
- $195.14 – $269.44
- Volume
- 1.54M
- Avg. volume
- 647.87K
Price performance
STE price history
1M range · 19 trading sessions · Daily adjusted prices
STE closed at $205.04 after 19 trading sessions, down 13.80% for the selected period.
- Last close
- $205.04
- Period change
- -13.80%
- Period low
- $205.04
- Period high
- $237.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $206.24 | $207.70 | $205.00 | $205.04 | 1.54M |
| Sep 17, 2026 | $210.81 | $210.815 | $206.97 | $208.04 | 765.55K |
| Sep 16, 2026 | $209.34 | $213.48 | $208.335 | $209.90 | 639.52K |
| Sep 15, 2026 | $212.64 | $214.02 | $210.19 | $210.28 | 779K |
| Sep 14, 2026 | $213.92 | $216.67 | $210.795 | $213.66 | 742.44K |
| Sep 11, 2026 | $214.00 | $214.21 | $209.59 | $210.76 | 595.42K |
| Sep 10, 2026 | $213.52 | $214.52 | $211.35 | $212.45 | 691.89K |
| Sep 9, 2026 | $216.99 | $218.245 | $213.29 | $215.09 | 499.1K |
| Sep 8, 2026 | $221.93 | $222.97 | $217.315 | $218.44 | 670.59K |
| Sep 4, 2026 | $223.20 | $225.44 | $221.435 | $224.59 | 568K |
| Sep 3, 2026 | $231.55 | $233.275 | $225.90 | $226.83 | 519.75K |
| Sep 2, 2026 | $229.23 | $236.085 | $225.545 | $230.35 | 468.49K |
| Sep 1, 2026 | $233.88 | $234.50 | $228.96 | $229.65 | 558.51K |
| Aug 31, 2026 | $231.69 | $233.055 | $229.845 | $232.64 | 860.21K |
| Aug 28, 2026 | $233.00 | $234.07 | $230.57 | $233.78 | 339.46K |
| Aug 27, 2026 | $235.25 | $236.12 | $232.81 | $232.97 | 532.73K |
| Aug 26, 2026 | $234.67 | $237.43 | $234.35 | $236.77 | 547.42K |
| Aug 25, 2026 | $237.00 | $240.34 | $235.02 | $236.44 | 906.75K |
| Aug 24, 2026 | $237.61 | $240.00 | $235.13 | $237.87 | 361K |
Latest STE news
The latest Smart Investors Daily articles mentioning STE.
Stock researchCompany · Overview
STE research
Overview
Company profile and research snapshot.
Company profile
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $256.67
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Piper Sandler | Overweight | — |
| Aug 7, 2026 | UBS | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
| May 13, 2026 | Keybanc | Overweight | — |
| Jul 22, 2025 | Keybanc | Overweight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 15, 2026
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
STERIS plc (STE) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:05 PM EDTCompany ParticipantsDaniel Carestio - President, CEO...
Yahoo · Sep 3, 2026
STERIS (STE) Stock Looks Reasonable On Earnings With Cash Flow Slightly Stretched
STERIS stock has delivered a positive 11.2% total return over the past five years, yet current checks suggest the shares now trade close to a fair level rather than offering an obvious discount. The intrinsic value estimate from a Discounted Cash Flow (DCF) framework is slightly below the recent market price, and the broader valuation tools also lean toward STERIS being on the expensive side. Over five years, STERIS has returned 11.2%, which points to modest long term gains rather than a...
Yahoo · Sep 2, 2026
STERIS (STE) Could Be 12% Below Fair Value As Conference Focus Returns
Conference appearance puts STERIS (STE) in the spotlight STERIS (STE) is drawing investor attention after confirming it will participate in the Morgan Stanley Healthcare Conference in New York on September 15, 2026, with CEO Dan Carestio scheduled to present. STERIS shares trade at US$229.65 after a small pullback in the past week, while the 90 day share price return of 9.26% points to building momentum that contrasts with a year to date share price decline of 8.15% and a 1 year total...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
